Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 4/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | TACR2 | P21452 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15718299 | 0.93 | GRIN1 (0.40) | GRIN1GRIN2BL3MBTL1NTRK1GPBAR1 | |
| SCHEMBL15717380 | 0.88 | RET (0.39) | GRIN1GRIN2BL3MBTL1NTRK1GPBAR1 | |
| SCHEMBL17309051 | 0.88 | GRIN2B (0.35) | GRIN1GRIN2BNTRK1 | |
| SCHEMBL15718306 | 0.86 | NTRK1 (0.40) | GRIN1GRIN2BNTRK1GPBAR1TACR2 | |
| SCHEMBL17309068 | 0.86 | CACNA1H (0.33) | NTRK1 | |
| SCHEMBL15764750 | 0.85 | KCNH2 (0.40) | GPBAR1PTGDR2 | |
| SCHEMBL15718173 | 0.84 | GPBAR1 (0.38) | GRIN1GRIN2BNTRK1GPBAR1PTGDR2 | |
| SCHEMBL15718359 | 0.83 | GPBAR1 (0.41) | GRIN1GRIN2BGPBAR1PTGDR2 | |
| SCHEMBL15764709 | 0.82 | GRIN1 (0.36) | GRIN1GRIN2BNTRK1GPR119TACR2 | |
| SCHEMBL15739668 | 0.81 | L3MBTL1 (0.38) | GRIN1GRIN2BL3MBTL1GPBAR1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160333012-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2016-11-17 | — | — | US | disclosed |
| US-20150011522-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2015-01-08 | — | — | US | disclosed |
| US-8871754-B2 | Compounds and compositions for the treatment of parasitic diseases | IRM LLC (BM) | 2014-10-28 | — | — | US | disclosed |
| US-20140155367-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011522-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | GRIN1 1919/4885GRIN2B 3351/4885L3MBTL1 3708/4885 |
| US-20140155367-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | GRIN1 1919/4885GRIN2B 3351/4885L3MBTL1 3708/4885 |
| US-20160333012-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | GRIN1 1919/4885GRIN2B 3351/4885L3MBTL1 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.